US 11,865,147 B2
Methods for reducing purine content and alleviating disorder of uric acid metabolism
Hsieh-Hsun Ho, Tainan (TW); Ching-Wei Chen, Tainan (TW); Yi-Wei Kuo, Tainan (TW); and Jui-Fen Chen, Tainan (TW)
Assigned to GLAC BIOTECH CO., LTD., Tainan (TW)
Filed by GLAC BIOTECH CO., LTD., Tainan (TW)
Filed on Dec. 6, 2021, as Appl. No. 17/457,758.
Claims priority of application No. 110107159 (TW), filed on Feb. 26, 2021.
Prior Publication US 2022/0273734 A1, Sep. 1, 2022
Int. Cl. A61K 35/747 (2015.01); A61P 19/06 (2006.01); C12N 1/20 (2006.01); C12P 1/04 (2006.01); A23L 33/135 (2016.01); A23L 33/00 (2016.01); C12R 1/25 (2006.01)
CPC A61K 35/747 (2013.01) [A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61P 19/06 (2018.01); C12N 1/205 (2021.05); C12P 1/04 (2013.01); A23V 2002/00 (2013.01); A23V 2400/143 (2023.08); A23V 2400/169 (2023.08); A23V 2400/173 (2023.08); C12R 2001/25 (2021.05)] 8 Claims
OG exemplary drawing
 
1. A method for reducing blood uric acid level in a subject, comprising administering to the subject in need thereof a composition containing Lactobacillus plantarum TSP05, Lactobacillus fermentum TSF331 and Lactobacillus reuteri TSR332 which are respectively deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession numbers CGMCC 16710, CGMCC 15527 and CGMCC 15528,
wherein a ratio of a number of Lactobacillus plantarum TSP05, to that of Lactobacillus fermentum TSF331, and to that of Lactobacillus reuteri TSR332 is 1:0.6:0.6.